Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib in the Treatment of Recurrent High-grade Glioma： an Open-label Single-arm, Phase 2 Trials

NCT04822805 is registered in ClinicalTrials.gov with First People's Hospital of Hangzhou as lead sponsor.

NCT NCT04822805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04822805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib in the Treatment of Recurrent High-grade Glioma： an Open-label Single-arm, Phase 2 Trials
Lead sponsor
First People's Hospital of Hangzhou
Phase
Phase 2
Overall status
Unknown status
Start date
April 13, 2020
Completion date
March 30, 2023
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent high-grade glioma